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The effects of polygenic risk for psychiatric
disorders and smoking behaviour on psychotic
experiences in UK Biobank
Judit García-González 1, Julia Ramírez 2, David M. Howard 3,4, Caroline H. Brennan1, Patricia B. Munroe2,5 and
Robert Keers1
Abstract
While psychotic experiences are core symptoms of mental health disorders like schizophrenia, they are also reported
by 5–10% of the population. Both smoking behaviour and genetic risk for psychiatric disorders have been associated
with psychotic experiences, but the interplay between these factors remains poorly understood. We tested whether
smoking status, maternal smoking around birth, and number of packs smoked/year were associated with lifetime
occurrence of three psychotic experiences phenotypes: delusions (n= 2067), hallucinations (n= 6689), and any
psychotic experience (delusions or hallucinations; n= 7803) in 157,366 UK Biobank participants. We next calculated
polygenic risk scores for schizophrenia (PRSSCZ), bipolar disorder (PRSBP), major depression (PRSDEP) and attention
deficit hyperactivity disorder (PRSADHD) in 144,818 UK Biobank participants of European ancestry to assess whether
association between smoking and psychotic experiences was attenuated after adjustment of diagnosis of psychiatric
disorders and the PRSs. Finally, we investigated whether smoking exacerbates the effects of genetic predisposition on
the psychotic phenotypes in gene-environment interaction models. Smoking status, maternal smoking, and number
of packs smoked/year were associated with psychotic experiences (p < 1.77 × 10−5). Except for packs smoked/year,
effects were attenuated but remained significant after adjustment for diagnosis of psychiatric disorders and PRSs (p <
1.99 × 10−3). Gene-environment interaction models showed the effects of PRSDEP and PRSADHD (but not PRSSCZ or
PRSBP) on delusions (but not hallucinations) were significantly greater in current smokers compared to never smokers
(p < 0.002). There were no significant gene-environment interactions for maternal smoking nor for number of packs
smoked/year. Our results suggest that both genetic risk of psychiatric disorders and smoking status may have
independent and synergistic effects on specific types of psychotic experiences.
Introduction
Psychotic experiences, such as hallucinations (unreal
visual or auditory perceptions) and delusions (unreal beliefs
or impressions, i.e. conspiracy against self, unreal commu-
nications or signs), are reported by 5–10% of the general
population1. Psychotic experiences are core symptoms of
severe mental disorders, such as schizophrenia, and there-
fore may be an indicator of risk for mental health problems
even in apparently healthy individuals. Understanding their
aetiology could help identify individual susceptibility for
different mental health outcomes and develop tailored pre-
vention and intervention strategies.
Genetic factors influence psychotic experiences, explain-
ing between 30% and 50% of the variance in twin studies2,3
and common genetic variation explaining between 3% and
17% of the variance in molecular genetic studies4,5. Twin
studies also suggest that the genetic component of psychotic
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experiences is shared with psychiatric disorders such as
schizophrenia, bipolar disorder, depression and attention
deficit hyperactivity disorder (ADHD)6. Large genome-wide
studies of psychotic experiences in UK Biobank (UKB)
confirm these findings: polygenic risk scores (PRS) of schi-
zophrenia, bipolar disorder, depression, and ADHD explain
0.11%, 0.06%, 0.32% and 0.05% of the variance in psychotic
experiences, respectively7. Linkage disequilibrium score
regression (LDSC) indicates the genetic correlation esti-
mates between psychotic experiences and schizophrenia,
bipolar disorder, depression and ADHD are 0.21, 0.15, 0.46
and 0.247.
In addition to genetic influences, environmental factors
explain between 50% and 70% of the variance in psychotic
experiences3. Smoking is one of the best established envir-
onmental risk factors associated with the occurrence of
psychotic experiences in case-control studies of schizo-
phrenia and bipolar disorder, as well as in population-based
samples. Longitudinal studies suggest that continued
smoking is a causal factor for psychotic experiences among
people with the first episode of psychosis8, schizophrenia,
and bipolar disorder patients9. The observation of a dose-
response effect in prospective studies10–13, together with
recent Mendelian randomization studies14, further support a
causal effect of smoking on the occurrence of psychotic
experiences. In addition, the associations between lifetime
tobacco use and subsequent psychotic experiences15,16 in the
general population remained significant after adjusting for
other psychiatric disorders16, suggesting that smoking may
lead to psychotic experiences independently from mental
health status.
Associations between other smoking phenotypes and
psychotic experiences are less well-established. There is
much less evidence for an increased risk of psychotic
experiences in former smokers, leading some to suggest
that the effects of smoking are reversible17,18. However, it
is still unclear whether these findings are false positives
resulting from a lack of power in relatively small samples.
Maternal smoking during pregnancy is associated with
psychotic experiences in offspring19. However within-
family studies suggest that once familial factors are taken
into account, maternal smoking during pregnancy has no
effect on the risk of psychotic experiences20.
Despite evidence showing associations between genetic
risk for psychiatric disorders and psychotic experiences6,7,
and a number of studies showing associations between
smoking and psychotic experiences17,21–23, the interplay
between smoking and genetic risk on psychotic experi-
ences remains unknown. There are studies showing that
PRSs for psychiatric disorders are associated with smok-
ing24–27. This suggests that smoking may not be only a
casual factor in the development of psychotic experiences,
but that common genetic factors may affect both smoking
and psychotic experiences. However, no studies have
tested whether PRSs for psychiatric disorders and smok-
ing make independent contributions to psychotic experi-
ences. Significant gene-environment interactions (GxE)
have been reported for several psychiatric traits including
schizophrenia and depression28–30, but studies are yet to
explore whether there is an interaction between smoking
and PRSs for psychiatric disorders on psychotic experi-
ences. That is, whether the effects of genetic risk are
greater for individuals exposed to smoking.
Our first objective was to investigate whether smoking
status (current, former or never smoker), number of packs
smoked per year and maternal smoking around birth were
associated with lifetime delusions or hallucinations or any
psychotic experience (delusions or hallucinations) in the
UKB cohort. We also tested whether the effects of
smoking remained significant after adjustment for diag-
nosis of depression, ADHD and psychotic disorders
(schizophrenia, mania, hypomania, bipolar or manic
depression, and schizotypal or delusional disorders), as
well as genetic risk for these disorders, captured by PRSs
for depression (PRSDEP), ADHD (PRSADHD), schizo-
phrenia (PRSSCZ) and bipolar disorder (PRSBP). Our sec-
ond objective was to investigate whether the effects of
smoking on psychotic experiences were exacerbated by
genetic risk by testing additive and multiplicative GxE
between these variables. We interrogated whether being a
current, former or never a smoker; smoking more packs
of cigarettes per year; or being exposed to maternal
smoking around birth influenced the effects of PRSs on
having hallucinations, delusions, or any of the two. When
significant interactions between smoking and PRS were
identified, we carried out sensitivity analyses excluding
people with psychotic disorders. An overview of the study
design is provided in Fig. 1.
Methods
UK Biobank sample
The sample was drawn from UKB, a population-based
cohort from the United Kingdom with ~500,000 partici-
pants. From those, 157,366 participants completed an online
mental health questionnaire. A detailed description of the
mental health questionnaire has been provided elsewhere31.
Ethical approval was provided by UKB (Application
ID#42423) and all participants gave written consent.
Measures
Psychotic experiences
Psychotic experiences were categorised based on the
Composite International Diagnostic Interview included in
the mental health questionnaire. Three outcomes were
defined: delusions, hallucinations, and any psychotic
experience. Delusions were ascertained as individuals
reporting lifetime delusions of reference and/or persecu-
tory delusions (Field IDs: 20474, 20468). Hallucinations
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were ascertained as individuals reporting lifetime visual
and/or auditory hallucinations (Field IDs: 20471, 20463).
Any lifetime psychotic experiences were ascertained as a
positive response to any of the four symptom questions
(Field IDs: 20474, 20468, 20471, 20463). Controls were
defined as individuals that did not endorse lifetime psy-
chotic experiences. A more detailed description of the
outcome variables is provided in the Supplementary
Tables 1–3.
Smoking
Three smoking outcomes were defined using the UKB
baseline questionnaire: smoking status (Field ID 20116),
pack years of smoking (Field ID 20161) and maternal
smoking around birth (Field ID 1787). The smoking status
phenotype consisted of never smoker, former smokers and
current smokers. Pack years of smoking were calculated
for former and current smokers and it was defined as the
number of cigarettes smoked per day, divided by twenty,
multiplied by the number of years of smoking. Cases for
maternal smoking were defined as individuals endorsing
‘Yes’ for the question ‘Did your mother smoke regularly
around the time when you were born?’.
Other psychiatric disorders
Lifetime depression, ADHD, schizophrenia, mania,
hypomania, bipolar or manic depression, and any other
type of psychotic disorder were defined using both the
UKB baseline and mental health questionnaires (Supple-
mentary Tables 4 and 5).
UKB genetic dataset
The data release contained 488,377 individuals geno-
typed on either the UKB Axiom or the UK BiLEVE Axiom
arrays. Genotype data were imputed centrally by UKB
with IMPUTE2 using the Haplotype Reference Con-
sortium panel32. UKB also provided metrics for quality
control that were used to exclude individuals with poor
genotype call rate (>5%) and discordance between the
self-reported sex and the sex inferred from the genotypes.
The first two principal components provided by UKB
were used in a k-means clustering algorithm33 to identify
Fig. 1 Detailed flowchart of the analytical approach. UKB UK Biobank cohort. PRSs polygenic risk scores for schizophrenia (PRSSCZ), depression
(PRSDEP), ADHD (PRSADHD) and Bipolar disorder (PRSBP). GWA genome-wide association. ADHD Attention deficit hyperactivity disorder.
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a genetically homogeneous subsample. Related individuals
were identified for each phenotype separately using the R
package ‘ukbtools’34 and one individual from related
pairs/trios were excluded (kinship coefficient > 0.0884).
Details on the quality control (QC) of genetic data and
sample sizes after QC exclusion are provided in Supple-
mentary Table 6.
PRSs
We calculated PRSSCZ, PRSDEP, PRSADHD and PRSBP for
each UKB participant using the software PRSice-235 and
summary statistics from four recent genome-wide asso-
ciation studies GWAS of these disorders (Supplementary
material)36–39. Logistic regression models were used to
explore the association between PRSSCZ, PRSDEP,
PRSADHD and PRSBP and psychotic experiences using
PRSice-235. Analyses included the first ten principal
components and genotyping batch as covariates.
Main effect analyses
Regression models were constructed to assess the
association between maternal smoking, smoking status
and number of packs smoked per year and psychotic
experiences. To test whether the association between
smoking and psychotic experiences was independent of
diagnosis for psychiatric disorders and genetic predisposi-
tion, models were rerun adjusting for: diagnosis for psy-
chotic disorders, depression, and ADHD, as well as the PRS
with the highest predictive ability (p-value threshold= 0.2)
on psychotic experiences.
Interaction effect analyses
We explored whether there were GxE between each of
the PRSs and smoking on psychotic experiences (i.e.
whether the effects of genetic risk differed among current,
former or never smokers, among smokers that consumed
more packs of cigarettes per year, and among individuals
whose mothers smoked around time of participants’
birth). Interactions were tested on the multiplicative and
additive scales using logistic and linear regressions,
respectively. Interactions on the multiplicative scale assess
whether the joint effect of the PRS and smoking is greater
than the product of their individual effects. Interactions
on the additive scale assess whether the joint effect of
smoking and the PRS is greater than the sum of their
individual effects. Modelling multiplicative and additive
GxE using linear and logistic regressions has been
described elsewhere29,30,40.
In the GxE regression models, we included individuals
from UKB with genetic, smoking and psychotic experi-
ences data (n= 143,320 for any psychotic experience, n=
143,043 for hallucinations, and n= 143,245 for delusions).
Independent variables were the PRSDEP, PRSADHD,
PRSSCZ or PRSBP for each individual, smoking phenotype,
ten principal components and genotyping batch. Depen-
dent variables were lifetime occurrence of hallucinations,
delusions or any psychotic experience. Models also
included the interaction of smoking and PRS with geno-
typing batch and the principal components, to control for
the effect of these covariates on the interaction term41. To
examine whether the GxE was significant after multiple
testing correction (p < 0.0021 based on 24 models under
additive and multiplicative models: 0.05/24= 0.0021), we
used the anova function from R package ‘car’. All models
were constructed in R (3.5.1).
Sensitivity analyses
The inclusion of individuals with psychotic disorders
(Supplementary Table 4) may inflate the variance
explained by the PRSs and lead to false-positive GxE.
Therefore, we repeated the significant interaction effect
analysis after excluding individuals that met the criteria
for psychotic disorders.
Results
In all, 157,366 individuals completed the mental health
questionnaire. From those, 2067 reported delusions, 6689
hallucinations and 7803 any psychotic experience. In all,
953 individuals had both lifetime delusions and halluci-
nations. Sample sizes for controls were 155,182, 150,336
and 149,289 for delusions, hallucinations, and any psy-
chotic experience, respectively.
For the smoking variables derived from the full cohort,
273,542 individuals reported that they never smoked,
173,072 were former smokers and 52,979 were current
smokers. The mean number of packs per year smoked was
23.4 (SD= 18.8). In all, 126,632 individuals reported that
their mothers had smoked around the participant’s birth,
whereas 306,266 reported the opposite. Table 1 includes
demographic, psychiatric and behavioural characteristics
of the sample before genetic data QC. Supplementary
Table 7 shows the number of individuals with psychotic
experiences stratified by smoking status, maternal smok-
ing and mean number of packs smoked per year after
genetic data QC.
Smoking and psychotic experiences
The odds of having delusions, hallucinations or any
psychotic experience was significantly higher in current or
former tobacco users when compared with non-users, and
in participants whose mothers smoked around the time of
birth (Table 2). There was a positive linear relationship
between the number of packs of cigarettes and risk of
psychotic experiences (Table 2). Associations between
smoking and the likelihood of having psychotic experi-
ences were strongest for continued tobacco smoking
(current smoking vs never smoked). Associations were
attenuated after adjustment for diagnosis of psychotic
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experiences, depression and ADHD but remained sig-
nificant. Only packs smoked per year on occurrence of
delusions did not pass the significance threshold after
multiple testing correction (p < 0.0125) (Table 2).
The PRSSCZ, PRSDEP, PRSADHD and PRSBP were sig-
nificantly associated with psychotic experiences (Fig. 2)
and with smoking behaviour (Supplementary Fig. 1). The
proportion of variance in psychotic experiences explained
by PRSs was small, the highest was for PRSSCZ, which
predicted 0.89% of the variance for lifetime delusions
(Fig. 2a). Results were dependent on the type of psychotic
experience: PRSSCZ and PRSBP explained almost double
the percentage of the variance for delusions than for
hallucinations (Fig. 2a, d), and p-values for PRSADHD
passed multiple testing correction for hallucinations and
any psychotic experience, but not for delusions (Fig. 2c).
Therefore, it is possible that genetic risk confounds the
relationship between smoking and psychotic experiences. To
test this hypothesis, we included PRSSCZ, PRSDEP, PRSADHD
and PRSBP as covariates in the analyses. All the regression
models (except packs smoked per year on delusions and
hallucinations) remained significant after the inclusion of the
PRSSCZ, PRSDEP, PRSADHD and PRSBP (Table 2).
Interaction between genetic risk of psychiatric disorders
and smoking on psychotic experiences
We found significant additive interactions between
PRSADHD and PRSDEP (but not PRSSCZ and PRSBP) and
smoking status (current vs never smoker) on reporting
lifetime delusions. That is, the combined effect of
PRSADHD and smoking, or PRSDEP and smoking was sig-
nificantly greater than the sum of their individual effects
(Fig. 3 and Supplementary Table 8 for OR and β values).
However, there were no significant interactions between
PRSs and smoking status for hallucinations or any psy-
chotic experiences (Fig. 3).
To ensure that the significant interaction for
PRSADHD and PRSDEP was not entirely driven by par-
ticipants with a diagnosis of bipolar disorder or schi-
zophrenia, we excluded individuals meeting criteria for
diagnosis of psychotic disorders (Supplementary Table
9) and repeated the GxE analyses. All the interaction
terms remained significant (Supplementary Fig. 2 and
Supplementary Table 10).
There were no significant interactions between the PRSs
and maternal smoking, nor between the PRSs and number
of packs per year (Supplementary Tables 11 and 12).
Table 1 Demographic, psychiatric and behavioural characteristics of the sample.
Any psychotic experience Delusions Hallucinations
Cases
n= 7803
Controls
n= 149,289
Cases
n= 2067
Controls
n= 155,182
Cases
n= 6689
Controls
n= 150,336
Age—[mean years (SD)] 54.6 (7.8) 56 (7.7) 53.8 (7.9) 55.9 (7.7) 54.7 (7.8) 56 (7.7)
Males N [%] 3082 [39.5%] 64,940 [43.5%] 1000 [48.4%] 67,193 [43.3%] 2535 [37.9%] 65,546 [43.6%]
Behavioural/psychiatric during lifetime (Self-reported in Mental Health Questionnaire)
Depression N [%] 4627 [59.3%] 48,071 [32.2%] 1482 [71.7%] 51,303 [33.06%] 3860 [57.7%] 48,859 [32.5%]
ADHD N [%] 22 [0.28%] 100 [0.07%] 11 [0.53%] 122 [0.08%] 15 [0.22%] 115 [0.08%]
Schizophrenia N [%] 125 [1.60%] 0 [0%] 109 [5.27%] 46 [0.03%] 100 [1.49%] 55 [0.04%]
Mania, hypomania, bipolar or manic-depression
N [%]
358 [4.59%] 423 [0.28%] 255 [12.34%] 573 [0.37%] 268 [4.00%] 556 [0.37%]
Any other type of psychosis or psychotic illness
N [%]
358 [4.59%] 0 [0%] 272 [13.16%] 319 [0.21%] 270 [4.04%] 324 [0.22%]
Demographics
Migrant [Yes %] 570 [7.3%] 9554 [6.4%] 159 [7.7%] 9932 [6.4%] 482 [7.2%] 9622 [6.4%]
Adverse life experiences 7077 [90.7%] 114,803 [76.9%] 1914 [92.6%] 120,111 [77.4%] 6060 [90.6%] 115,759 [77.0%]
Socio economic status (as per house ownership)
Own outright N [%] 3628 [46.5%] 82,557 [55.3%] 858 [41.5%] 85,350 [55.0%] 3157 [47.2%] 82,985 [55.2%]
Own mortgage N [%] 3074 [39.4%] 57,028 [38.2%] 804 [38.9%] 59,435 [38.3%] 2622 [39.2%] 58,330 [38.8%]
Rent social N [%] 523 [6.7%] 3583 [2.4%] 190 [9.2%] 4035 [2.6%] 441 [6.6%] 3758 [2.5%]
Rent private N [%] 328 [4.2%] 3434 [2.3%] 132 [6.4%] 3569 [2.3%] 261 [3.9%] 3458 [2.3%]
Accommodation rent free N [%] 86 [1.1%] 896 [0.6%] 27 [1.3%] 931 [0.6%] 74 [1.1%] 902 [0.6%]
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Discussion
Our study investigated whether smoking is associated
with the occurrence of psychotic experiences indepen-
dently from diagnosis of psychotic disorders, depression
or ADHD, or genetic predisposition for these disorders.
We also tested whether the effects of smoking were
modulated by the genetic risk in gene-environment
interaction models. We found smoking status, maternal
smoking and number of packs smoked per year were all
significantly associated with increased risk of psychotic
experiences. GxE modelling indicated the effects of two
PRSs (DEP & ADHD) on delusions was significantly greater
in current smokers compared to never smokers. These
results suggest both genetic risk and smoking behaviour
contribute to specific types of psychotic experiences.
A few previous studies have assessed PRS-environment
interactions on psychotic experiences finding that higher
genetic risk exacerbates environmental effects. However,
these studies have focused exclusively on genetic risk of
schizophrenia and environmental factors such as stress42
and birth weight43. Our study is the first one to explore
PRS by environment interactions with smoking on psy-
chotic experiences and the first to explore these effects in
the context of genetic risk of depression, bipolar disorder
and ADHD. Further, our study had greater power than
previous ones because we used at least 30 times larger
sample sizes, we calculated multiple PRSs at higher p-
values that increased the predictive power of the genetic
score, and we used the largest GWAS summary statistics
available to date.
The interaction of smoking status with PRSDEP, but not
with PRSSCZ or PRSBP, on predicting delusions is of par-
ticular interest. Delusions of reference and persecution
are classified as some of the core symptoms of psychotic
disorders (i.e. schizophrenia and bipolar disorder) but
they are rarely part of the diagnostic criteria for depres-
sion44. Wooton et al.14 reported that genetic risk for
depression increased smoking, but there was unclear
evidence for genetic risk for schizophrenia increasing
smoking. Our finding that PRSDEP (but not PRSSCZ or
PRSBP) interacts with smoking on predicting psychotic
experiences points at a stronger relationship between
Table 2 Phenotypic relationships between smoking and psychotic experiences within UKB. Logistic regression models
were used to assess the association between smoking and three psychotic experiences phenotypes.
Unadjusteda Adjusted for psychiatric
disordersb
Adjusted for psychiatric
disorders andPRSsc
OR (95% CI) p OR (95% CI) p OR (95% CI) p
Any psychotic experience
Former vs never smoking 1.22 (1.16–1.28) 4.99 × 10−14 1.16 (1.10–1.22) 2.89 × 10−8 1.15 (1.09–1.21) 2.87 × 10−7
Current vs never smoking 1.76 (1.62–1.91) 4.76 × 10−42 1.47 (1.35–1.60) 3.76 × 10−19 1.45 (1.33–1.58) 1.08 × 10−17
Maternal smoking 1.26 (1.19–1.33) 5.89 × 10−17 1.20 (1.14–1.27) 5.87 × 10−11 1.19 (1.13–1.26) 6.98 × 10−10
Packs smoked per year 1.006 (1.004–1.008) 4.61 × 10−7 1.004 (1.001–1.006) 2.95 × 10−3 1.003 (1.001–1.006) 7.17 × 10−3
Delusions
Former vs never smoking 1.28 (1.16–1.41) 1.68 × 10−6 1.18 (1.07–1.31) 1.29 × 10−3 1.17 (1.05–1.29) 3.90 × 10−3
Current vs never smoking 2.21 (1.9–2.55) 9.74 × 10−27 1.61 (1.38–1.87) 9.41 × 10−10 1.57 (1.35–1.83) 8.13 × 10−9
Maternal smoking 1.28 (1.15–1.42) 3.17 × 10−6 1.20 (1.08–1.34) 8.09 × 10−4 1.19 (1.06–1.32) 2.06 × 10−3
Packs smoked per year 1.009 (1.005–1.013) 4.73 × 10−6 1.005 (1.000–1.009) 0.0383 1.004 (0.999–1.008) 0.0740
Hallucinations
Former vs never smoking 1.21 (1.14–1.28) 2.66 × 10−11 1.15 (1.09–1.22) 8.05 × 10−7 1.14 (1.08–1.21) 4.76 × 10−6
Current vs never smoking 1.76 (1.61–1.92) 8.08 × 10−37 1.49 (1.36–1.63) 2.36 × 10−18 1.47 (1.34–1.61) 4.86 × 10−17
Maternal smoking 1.26 (1.19–1.34) 4.47 × 10−15 1.21 (1.14–1.28) 4.66 × 10−10 1.20 (1.13–1.27) 3.92 × 10−9
Packs smoked per year 1.005 (1.003–1.008) 1.77 × 10−5 1.003 (1.001–1.006) 0.0101 1.003 (1.001–1.006) 0.0185
For the predictor ‘packs smoked per year’, OR represents the increase in odds ratio for one unit increase in the number of packs smoked per year.
OR Odds ratio, p p-value.
Significance was declared at p < 0.0125 after Bonferroni correction (based on four tests, one per smoking phenotype).
aUnadjusted model; assessed the phenotypic relationship between psychotic experiences and smoking using logistic regression models.
bAdjusted model; included as covariates: diagnosis for psychotic disorders, ADHD and depression.
cAdjusted model; included as covariates: diagnosis for psychotic disorders, depression and ADHD, as well as PRS for schizophrenia, PRS for depression, PRS for ADHD
and PRS for Bipolar disorder.
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smoking and depression than between smoking and
schizophrenia or between smoking and bipolar disorder.
Our sensitivity analyses, where the interaction remained
significant after excluding people with psychotic dis-
orders, supports this hypothesis.
In line with previous studies, we found significant
associations between the smoking phenotypes and psy-
chotic experiences10–13,17, and between PRSSCZ, PRSDEP,
PRSADHD and PRSBP and the smoking phenotypes and
psychotic experiences25,36,45,46. These findings suggest
Fig. 2 Prediction of psychotic experiences in UKB using PRSs for schizophrenia (a), depression (b), ADHD (c) and bipolar disorder (d). Each panel is
divided into types of psychotic experiences. The Y axis represents variance of psychotic experience explained by the PRS in the liability scale
(Nagelkerke R2). The X axis represents different genetic association p-value thresholds used to build the PRS. The p-values of the association between
the PRSs and psychotic experiences are listed above of the bars.
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Fig. 3 Associations between polygenic risk score for a schizophrenia (PRSSCZ), b depression (PRSDEP), c ADHD (PRSADHD) and d bipolar disorder (PRSBP)
and occurrence of psychotic experiences (PE) under the additive model. Current smokers are shown as blue squares, former smokers as orange
triangles, and never smokers as green circles. P values for the PRS × smoking status interactions are shown on the upper part of each plot. Significant
associations (p < 0.0021 based on 24 tests; 12 additive interactions and 12 multiplicative interactions) are highlighted in bold. The effects of PRSDEP
and PRSADHD on the probability of having delusions are greater among current smokers than former and never smokers.
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that the relationship between the smoking variables and
psychotic experiences may be confounded by shared
genetic influences. However, the effects of smoking
remained very similar after adjusting for PRSs, providing
little evidence of genetic confounding by common genetic
variation associated with schizophrenia, depression,
ADHD and bipolar disorder. Previous studies have shown
that the effects of smoking on psychotic experiences
remain significant after adjustment for psychiatric dis-
orders16. However, this is the first study to show these
effects also remain significant after adjustment for genetic
risk of specific psychiatric disorders.
The effects of maternal smoking after adjusting for the
PRSs are also interesting. Previous within-family studies
suggest that, once unmeasured familial factors are taken
into account, maternal smoking has little effect on psy-
chotic disorders20. In the current study, the effects of
maternal smoking persisted following adjustment for
PRSSCZ, PRSDEP PRSADHD and PRSBP. This tentatively
suggests that genetic risk for these disorders does not
confound the relationship between maternal smoking and
psychotic experiences. Nevertheless, the PRSs tested only
capture a small fraction of the genetic risk for psychiatric
disorders. Replication of these effects using more pow-
erful estimates of genetic risk will be required to test this
hypothesis.
There are some limitations of this study: it is retro-
spective meaning it is subject to recalling biases, which
occur when participants do not accurately remember past
experiences, and this can lead to spurious results. We
have relied on self-reported data, which might be affected
by different conceptions of what it is a psychotic experi-
ence. There were 351 individuals that completed the UKB
mental health questionnaire that may have also partici-
pated in the Psychiatric Genomic Consortium cohorts
analysed by Wray et al.37. The sample overlap was mini-
mal, with 0.079% for the discovery sample (351/446,238),
and 0.242% for the target sample (351/144,818). The
overlap was identified using a checksum-based approach
as described in Howard et al.47 and the impact over this
overlap is unknown. We reported an interaction between
genetic risk and smoking, but the percentage of variance
explained by the PRSs was very low (<1%), therefore
further work is required to understand the remaining
sources of phenotypic variance. There is also evidence of a
‘healthy volunteer’ bias in UKB48, especially among people
who completed the mental health questionnaire31, which
may make this study not fully representative of the general
population. Finally, the present study was focused on
individuals of European ancestry therefore these results
might not be valid for other ancestries49.
Despite the limitations, we report for the first time that
smoking is associated with occurrence of psychotic
experiences after adjusting for genetic risk for mental
health and that current smokers with higher genetic risk
for depression and ADHD are more likely to experience
delusions but not hallucinations. These results emphasise
the importance of assessing environmental and genetic
factors jointly and separately, and exploring particular
types of psychotic experiences, as they can be differen-
tially associated with smoking or other risk factors. This
study also highlights the relationship between smoking
and depression, and between smoking and ADHD on the
occurrence of specific types of psychotic experiences in
the general population, encouraging further studies to
explore the effect of genetic risk for other psychiatric
disorders on psychosis. Taken together, our results sup-
port the distinction of types of psychotic symptoms, the
inclusion of environmental factors, and the study of cross-
disorder genetic predictors to inform biological mechan-
isms underlying psychotic experiences.
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